Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 12:54 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2905–2928 of 6,604 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Multi Center Clear all

Conditions: Acute Infection
Interventions: MeMed BV; Diagnostic Test
Lead sponsor: MeMed Diagnostics Ltd.; Industry
Eligibility: 90 Days and older
Enrollment: 1,384 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2020
U.S. locations: 9
States / cities: Baltimore, Maryland • Boston, Massachusetts • New York, New York + 5 more

Conditions: Pancreatic Ductal Adenocarcinoma, Pancreatic Cyst, Chronic Pancreatitis, Fatty Pancreas, Genetic Pancreatic Cancer, Genetic Pancreatitis, BRCA Mutation, Lynch Syndrome, FAP, Familial Atypical Multiple Mole-Melanoma, PALB2 Gene Mutation, Peutz-Jeghers Syndrome, Ataxia Telangiectasia
Interventions: Data collection; Other
Lead sponsor: H. Lee Moffitt Cancer Center and Research Institute; Other
Eligibility: 18 Years and older
Enrollment: 317 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Tampa, Florida

Conditions: Non-small Cell Lung Cancer
Interventions: Tecemotide (L-BLP25), Single low dose cyclophosphamide, Placebo; Biological · Drug
Lead sponsor: EMD Serono; Industry
Eligibility: 18 Years and older
Enrollment: 1,513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2015
U.S. locations: 49
States / cities: Fort Smith, Arkansas • Anaheim, California • Glendale, California + 41 more

Conditions: Coronary Disease, Coronary Arteriosclerosis, Hyperlipidemia
Interventions: torcetrapib/atorvastatin, atorvastatin; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 1,100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 127
States / cities: Birmingham, Alabama • Mobile, Alabama • Little Rock, Arkansas + 124 more

Conditions: Diabetes type2, Obesity
Interventions: RESET Liner, Sham; Device · Other
Lead sponsor: Morphic Medical Inc.; Industry
Eligibility: 22 Years to 65 Years
Enrollment: 264 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2029
U.S. locations: 27
States / cities: Gilbert, Arizona • Tucson, Arizona • Washington D.C., District of Columbia + 22 more

Conditions: Pancreatic Cyst
Interventions: 1). EUS-FNA plus MFB, 2). EUS-FNA Alone; Procedure
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 89 Years
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2025
U.S. locations: 3
States / cities: Irvine, California • Aurora, Colorado • Houston, Texas

Conditions: Healthy Volunteers, Patients, Pharmacokinetics, Renal Impairment
Interventions: TC-5214; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2011
U.S. locations: 2
States / cities: Orlando, Florida • Minneapolis, Minnesota

Conditions: Osteoarthritis, Rheumatoid Arthritis, Other Inflammatory Arthritis, Post-Traumatic Arthritis, Juvenile Rheumatoid Arthritis, Avascular Necrosis
Interventions: Total Knee Arthroplasty, Total knee replacement; Device
Lead sponsor: DePuy Orthopaedics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 149 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2007
U.S. locations: 3
States / cities: Greensboro, North Carolina • Austin, Texas • Lakewood, Washington

Conditions: Cellulite
Interventions: Soliton's Rapid Acoustic Pulse (RAP); Device
Lead sponsor: Soliton; Industry
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2021
U.S. locations: 4
States / cities: Scottsdale, Arizona • Chicago, Illinois • Chevy Chase, Maryland + 1 more

Conditions: Myelodysplastic Syndromes, Refractory Anemia With Excess Blasts, Chronic Myelomonocytic Leukemia, Cytopenia
Interventions: rigosertib sodium; Drug
Lead sponsor: Traws Pharma, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 14
States / cities: Stanford, California • Chicago, Illinois • Westwood, Kansas + 7 more

Conditions: Rheumatoid Arthritis
Interventions: Not listed
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 1
States / cities: Coral Springs, Florida

Conditions: Cervicogenic Headache, Neck Pain, Whiplash, Kyphotic and Reversed Cervical Curves
Interventions: Not listed
Lead sponsor: Logan College of Chiropractic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2010
U.S. locations: 1
States / cities: Chesterfield, Missouri

Conditions: Non-hodgkin Lymphoma, Multiple Myeloma
Interventions: Audio Tasks; Diagnostic Test
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 8
States / cities: Basking Ridge, New Jersey • Middletown, New Jersey • Montvale, New Jersey + 4 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Diolamine, Placebo; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 690 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2018
U.S. locations: 40
States / cities: Phoenix, Arizona • Tucson, Arizona • Fresno, California + 33 more

Conditions: Cancer, Tumor, Solid, Refractory Cancer
Interventions: TBX-3400; Biological
Lead sponsor: Taiga Biotechnologies, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Asthma
Interventions: ADC3680, Placebo, montelukast; Drug
Lead sponsor: Pulmagen Therapeutics; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 248 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 35
States / cities: Birmingham, Alabama • Huntington Beach, California • Riverside, California + 32 more

Conditions: Skin Wrinkling
Interventions: Emervel Deep Lidocaine, Juvederm Ultra Plus; Device
Lead sponsor: Galderma R&D; Industry
Eligibility: 18 Years and older
Enrollment: 162 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2012
U.S. locations: 11
States / cities: Los Angeles, California • San Francisco, California • New Haven, Connecticut + 8 more

Conditions: Secondary Hyperparathyroidism, Renal Failure, Chronic Renal Insufficiency
Interventions: Hectorol (doxercalciferol capsules), 0.5mcg; Drug
Lead sponsor: Genzyme, a Sanofi Company; Industry
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2007
U.S. locations: 17
States / cities: Phoenix, Arizona • Alhambra, California • Riverside, California + 14 more

Conditions: Breast Neoplasm Female, Breast Cancer
Interventions: Aminolevulinic Acid Hydrochloride, Eagle V1.2 Imaging System, Placebo; Drug · Device
Lead sponsor: SBI ALApharma Canada, Inc.; Industry
Eligibility: 18 Years and older · Female only
Enrollment: 57 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 7
States / cities: Stamford, Connecticut • Clearwater, Florida • Miami, Florida + 4 more

Conditions: Infections, Meningococcal
Interventions: Meningococcal (groups A, C, W and Y) oligosaccharide diphtheria CRM-197 conjugate Vaccine (Menveo); Biological
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 15 Years to 55 Years
Enrollment: 704 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2016 – 2017
U.S. locations: 36
States / cities: Birmingham, Alabama • Huntsville, Alabama • Chandler, Arizona + 27 more

Conditions: Traumatic Brain Injury, Posttraumatic Stress Disorder
Interventions: Cognitively Augmented Behavioral Activation, Treatment as Usual; Behavioral
Lead sponsor: VA Office of Research and Development; Federal
Eligibility: 18 Years to 55 Years
Enrollment: 73 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 2
States / cities: Portland, Oregon • Seattle, Washington

Conditions: Neoplasms
Interventions: Vemurafenib; Drug
Lead sponsor: Hoffmann-La Roche; Industry
Eligibility: 18 Years and older
Enrollment: 51 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2015
U.S. locations: 9
States / cities: Torrance, California • New Haven, Connecticut • Chicago, Illinois + 5 more

Conditions: Rheumatoid Arthritis
Interventions: adalimumab, methotrexate; Drug
Lead sponsor: Abbott; Industry
Eligibility: 18 Years and older
Enrollment: 148 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 1
States / cities: Abbott Park, Illinois

Conditions: Systemic Lupus Erythematosus (SLE)
Interventions: Anifrolumab, Standard of Care; Drug
Lead sponsor: Oklahoma Medical Research Foundation; Other
Eligibility: 18 Years to 70 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 5
States / cities: New Haven, Connecticut • Atlanta, Georgia • New York, New York + 1 more

Search by objective public record fields.

Establish MeMed BV™ Performance for Differentiating Bacterial From Viral Infection in Suspected Acute Infection Patients (APOLLO STUDY)

The Pancreas Interception Center (PIC) for Early Detection, Prevention, and Novel Therapeutics

Cancer Vaccine Study for Unresectable Stage III Non-small Cell Lung Cancer (START)

A Coronary IVUS Study to Compare Torcetrapib/Atorvastatin to Atorvastatin Alone in Subjects With Coronary Heart Disease

The RESET System Pivotal Clinical Trial (Protocol Revision K)

Evaluation of Pancreatic Cystic Lesions Via EUS-guided Fine Needle Aspiration With and Without Micro Forceps Biopsies

To Compare the Pharmacokinetics of a Single Oral Dose of TC-5214 in Subjects With Renal Impairment and With Subjects With Normal Renal Function

Randomized Fixed Bearing vs Mobile Bearing Cruciate Substituting TKA

Study of the Soliton Rapid Acoustic Pulse (RAP) Device for the Treatment of Cellulite

Efficacy and Safety of IV Rigosertib in MDS Patients With Excess Blasts Progressing After Azacitidine or Decitabine

An Observational Study of Dosage Patterns in Routine Clinical Practice in Patients With Rheumatoid Arthritis (ACT-LIFE)

Multi Cervical Unit Measures of Cervical Isometric Strength and Range of Motion: A Pilot Study

A Study of Voice as a Way to Monitor for Side Effects in People Receiving CAR T-Cell Therapy

Phase III Clinical Worsening Study of UT-15C in Subjects With PAH Receiving Background Oral Monotherapy

Study of TBX-3400 in Subjects With Solid Malignant Tumors Resistant or Refractory to Standard Therapies

A Study to Evaluate Efficacy and Safety of ADC3680 in Subjects With Inadequately-Controlled Asthma

Emervel® Deep Lidocaine vs. Juvederm® Ultra Plus in Treatment of Moderate to Severe Facial Wrinkles and Folds

Study of Safety and Efficacy of Doxercalciferol in Patients With Chronic Kidney Disease, Stage 3 or 4, and Secondary Hyperparathyroidism

Fluorescence Imaging of Carcinoma During Breast Conserving Surgery

Study to Assess the Safety and Immunogenicity of a Single Dose of GlaxoSmithKline's (GSK) Meningococcal MenACWY-CRM Vaccine (Menveo), Administered to Subjects 15 Through 55 Years of Age, Approximately 4-6 Years After Primary ACWY Vaccination

Cognitively Augmented Behavioral Activation for Veterans With Comorbid TBI/PTSD

A Study of Vemurafenib (RO5185426) in Participants With Metastatic or Unresectable Papillary Thyroid Cancer Positive for the BRAF V600 Mutation

Adalimumab in Combination With Methotrexate vs Methotrexate Alone in Early Rheumatoid Arthritis

Nature of Anifrolumab Impact on Vaccine-Emergent Immunity in SLE